FTY720 is an immune modulator and a synthetic analogue of sphingosine 1-phosphate (S1P), activated S1P receptors and is effective in experimental models of transplantation and autoimmunity.

FTY720 is a novel, once-daily, oral treatment in worldwide Phase III clinical development for the treatment of relapsing-remitting MS, the form of the disease that affects approximately 85% of ...

A study aiming to deliver Fingolimod (FTY720) loaded polymer scaffolds to enhance oral wound healing by modulating pro-regenerative immune cell migration associated with improved vascularization ...

Swiss drugmaker Novartis AG <NOVN.VX> said on Wednesday its FTY720 oral drug to treat multiple sclerosis reduced both relapses and disability progression.

FTY720 was found to directly bind to I2PP2A through a ceramide-binding domain resulting in inhibition of growth in the tested human lung cancer cell lines and A549-xenograft-derived tumors. The ...

FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis) was a double-blind, placebo-controlled study involving 1,272 patients in 22 countries to assess the ...

Novartis AG's <NOVN.VX> once-daily FTY720 pill reduced the number of attacks suffered by patients with multiple sclerosis (MS) after three years, according to data presented on Tuesday.

FTY720-related adverse events included dose-related, transient, generally asymptomatic heart rate reduction, infrequent transient AV conduction block, mild (1-3 mm Hg) blood pressure increase ...

A study aiming to deliver Fingolimod (FTY720) loaded polymer scaffolds to enhance oral wound healing by modulating pro-regenerative immune cell migration associated with improved vascularization ...

Novartis SA said one patient died and another developed a serious infection in tests of its FTY720 multiple sclerosis treatment. ``Novartis was recently notified of two infection-related incidents ...

He will be available for media questions during a press briefing at 11:00 a.m. CT/12:00 p.m. ET, on Tuesday, April 15, 2008, in the on-site Press Interview Room, room 182. If you are a member of ...